Kristen J Wells1,2,3, Tonya M Pan4,5, Coralia Vázquez-Otero6, Danielle Ung6, Amy E Ustjanauskas4,5, Dariana Muñoz7, Christine Laronga6,8, Richard G Roetzheim6,8, Marissa Goldenstein9, Claudia Carrizosa7, Sumayah Nuhaily10, Kenneth Johnson11, Marilyn Norton11, Elizabeth Sims12, Gwendolyn P Quinn6,8. 1. Department of Psychology, San Diego State University, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-4913, USA. kwells@mail.sdsu.edu. 2. University of California, San Diego Moores Cancer Center, La Jolla, CA, USA. kwells@mail.sdsu.edu. 3. SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA. kwells@mail.sdsu.edu. 4. University of California, San Diego Moores Cancer Center, La Jolla, CA, USA. 5. SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA. 6. University of South Florida, Tampa, FL, USA. 7. , San Diego State University Research Foundation, San Diego, CA, USA. 8. Moffitt Cancer Center, Tampa, FL, USA. 9. Department of Psychology, San Diego State University, 6363 Alvarado Court, Suite 103, San Diego, CA, 92120-4913, USA. 10. Emory University, Atlanta, GA, USA. 11. , South County Oncology and Hematology, Chula Vista, CA, USA. 12. Sharp HealthCare, San Diego, CA, USA.
Abstract
PURPOSE: To evaluate the barriers and facilitators to taking anti-hormonal medications among medically and historically underserved breast cancer survivors within the first 5 years post chemotherapy, radiation, and/or surgery. METHODS: The current study was framed within the National Institutes of Health Centers for Population Health and Health Disparities Model (NIHCPHHD Model). Twenty-five historically or medically underserved breast cancer survivors participated in an in-depth interview, in either English or Spanish. Interviews were audio recorded and transcribed verbatim. Interview data were analyzed using content analysis. RESULTS: Anti-hormonal medication adherence was facilitated in several ways, including establishing a routine of medication taking, leaving the medicine in a visible or easily accessible place, taking the medication with other medications, reducing the cost of medicine, using a pillbox, understanding the negative consequences of lack of adherence, and having positive interactions with physicians. Side effects were the most commonly mentioned barrier to medication adherence. CONCLUSIONS: Similar to other research, this qualitative study of medically and historically underserved breast cancer survivors in the USA found that side effects are the most frequently endorsed barrier to anti-hormonal medication adherence. Conversely, there were a number of facilitators of correct and consistent anti-hormonal medication use. The management of side effects is critically important to increase adherence to anti-hormonal medications. Health care providers, support providers, and caregivers can encourage breast cancer survivors to better adhere to anti-hormonal medications using a number of approaches that have been successful for other women.
PURPOSE: To evaluate the barriers and facilitators to taking anti-hormonal medications among medically and historically underserved breast cancer survivors within the first 5 years post chemotherapy, radiation, and/or surgery. METHODS: The current study was framed within the National Institutes of Health Centers for Population Health and Health Disparities Model (NIHCPHHD Model). Twenty-five historically or medically underserved breast cancer survivors participated in an in-depth interview, in either English or Spanish. Interviews were audio recorded and transcribed verbatim. Interview data were analyzed using content analysis. RESULTS: Anti-hormonal medication adherence was facilitated in several ways, including establishing a routine of medication taking, leaving the medicine in a visible or easily accessible place, taking the medication with other medications, reducing the cost of medicine, using a pillbox, understanding the negative consequences of lack of adherence, and having positive interactions with physicians. Side effects were the most commonly mentioned barrier to medication adherence. CONCLUSIONS: Similar to other research, this qualitative study of medically and historically underserved breast cancer survivors in the USA found that side effects are the most frequently endorsed barrier to anti-hormonal medication adherence. Conversely, there were a number of facilitators of correct and consistent anti-hormonal medication use. The management of side effects is critically important to increase adherence to anti-hormonal medications. Health care providers, support providers, and caregivers can encourage breast cancer survivors to better adhere to anti-hormonal medications using a number of approaches that have been successful for other women.
Entities:
Keywords:
Breast cancer; Breast neoplasms; Cancer; Medication adherence; Oncology
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman Journal: Breast Cancer Res Treat Date: 2006-03-16 Impact factor: 4.872
Authors: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: Alison Harrow; Ruth Dryden; Colin McCowan; Andrew Radley; Mark Parsons; Alastair M Thompson; Mary Wells Journal: BMJ Open Date: 2014-06-12 Impact factor: 2.692
Authors: Anna N Baglione; Jiaqi Gong; Mehdi Boukhechba; Kristen J Wells; Laura E Barnes Journal: IEEE Pervasive Comput Date: 2020-06-26 Impact factor: 3.175
Authors: Mehdi Boukhechba; Sonia Baee; Alicia L Nobles; Jiaqi Gong; Kristen Wells; Laura E Barnes Journal: IEEE EMBS Int Conf Biomed Health Inform Date: 2018-04-09
Authors: Kristen J Wells; Julia H Drizin; Amy E Ustjanauskas; Coralia Vázquez-Otero; Tonya M Pan-Weisz; Danielle Ung; Claudia Carrizosa; Christine Laronga; Richard G Roetzheim; Kenneth Johnson; Marilyn Norton; Rosa Cobian Aguilar; Gwendolyn P Quinn Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.603
Authors: Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell Journal: Curr Oncol Date: 2021-07-05 Impact factor: 3.677
Authors: Yiqi Pan; Sarah R Heisig; Pia von Blanckenburg; Ute-Susann Albert; Peyman Hadji; Winfried Rief; Yvonne Nestoriuc Journal: Breast Cancer Res Treat Date: 2018-01-12 Impact factor: 4.872
Authors: Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard; Stephen K Chia; Carolyn C Gotay Journal: BMC Cancer Date: 2018-07-11 Impact factor: 4.430